Calculation Formulas of Scoring System of survival in chronic myeloid leukemia (CML): The Sokal, Hasford, EUTOS and ELTS Scores.

Note: Exp – exponential function; Age is in years; Spleen is in cm below the costal margin; Platelet count is in * I09/L; Blasts, eosinophils and basophils are in percent of peripheral blood.
EUTOS, European Treatment and Outcome Study; ELTS, EUTOS long-term survival.

A source:
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789-99. https://pubmed.ncbi.nlm.nih.gov/6584184/
Thomas M, Irving J, Lennard A, Proctor S, Taylor P. Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia. Journal of Clinical Pathology. 2001;54(6):491-493. doi:10.1136/jcp.54.6.491. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1731441/pdf/v054p00491.pdf
Uz B, Buyukasik Y, Atay H, et al. EUTOS CML prognostic scoring system predicts ELN-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology. 2013;18(5):247-52. https://pubmed.ncbi.nlm.nih.gov/23540886/
Yahng SA, Jang EJ, Choi SY, et al. Comparison of Sokal, Hasford and EUTOS scores in terms of long-term treatment outcome according to the risks in each prognostic model: a single center data analyzed in 255 early chronic phase chronic myeloid leukemia patients treated with frontline imatinib mesylate. Blood 2012;120:Abstract 2794.
Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 2011;29:3944–5.  https://ascopubs.org/doi/full/10.1200/jco.2011.37.6962
Yamamoto E, Fujisawa S, Hagihara M, et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105(1):105-9. https://pubmed.ncbi.nlm.nih.gov/24450386/
Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48-56. https://pubmed.ncbi.nlm.nih.gov/26416462/ 
Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study DOI:10.2147/CMAR.S237467
Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann V S, Castagnetti F, Hasford J, Hehlmann R, Simonsson B. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2015. Article in press.
Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90: 850-8.

Read also:

Register on our website right now to have access to more learning materials!

Register

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies (Anthracycline Chemotherapy) – Online Calculator

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies (Anthracycline Chemotherapy)…

Read More

National Institutes of Health Stroke Scale (NIHSS) – Online calculator

The National Institutes of Health Stroke Scale (NIHSS) is a scale designed to assess the…

Read More

Charlson Comorbidity Index (CCI) Online Calculator

Charlson Comorbidity Index predicts 10-year survival in patients with multiple comorbidities.

Loading...

Email (indicate if you want the results to be sent to your email)

Date of assessment

---

Age *

<50 years

50–59 years

60–69 years

70–79 years

≥80 years

Myocardial infarction *

History of definite or probable MI (EKG changes and/or enzyme changes)

No

Yes

Congestive heart failure *

Exertional or paroxysmal nocturnal dyspnea and has responded to digitalis, diuretics, or afterload reducing agents

No

Yes

Peripheral vascular disease *

Intermittent claudication or past bypass for chronic arterial insufficiency, history of gangrene or acute arterial insufficiency, or untreated thoracic or abdominal aneurysm (≥6 cm)

No

Yes

Cerebrovascular accident or Transient ischemic attack *

History of a cerebrovascular accident with minor or no residua and transient ischemic attacks

No

Yes

Dementia *

Chronic cognitive deficit

No

Yes

Chronic obstructive pulmonary disease *

No

Yes

Connective tissue disease *

No

Yes

Peptic ulcer disease *

Any history of treatment for ulcer disease or history of ulcer bleeding

No

Yes

Liver disease *

Severe = cirrhosis and portal hypertension with variceal bleeding history, moderate = cirrhosis and portal hypertension but no variceal bleeding history, mild = chronic hepatitis (or cirrhosis without portal hypertension)

None

Mild

Moderate to severe

Diabetes mellitus *

None or diet-controlled

Uncomplicated

End-organ damage

Hemiplegia *

No

Yes

Moderate to severe chronic kidney disease *

Severe = on dialysis, status post kidney transplant, uremia, moderate = creatinine >3 mg/dL (0.27 mmol/L)

No

Yes

Solid tumor *

None

Localized

Metastatic

Leukemia *

No

Yes

Lymphoma *

No

Yes

AIDS *

No

Yes

---

Charlson Comorbidity Index

10-year survival

Details:

Reset

* Required

VariablePointsAge <50…

Read More

Multiple Myeloma Diagnostic Criteria – Online Calculator

Loading...

Email (indicate if you want the results to be sent to your email)

Date of assessment

---

≥1 of the following (A or B)

*

A. Clonal bone marrow plasma cells ≥10%

B. Biopsy-proven bony or extramedullary plasmacytoma

≥1 myeloma defining event (C1 or C2)

• C1. End organ damage attributable to underlying plasma cell disorder (≥1 of the following): *

o Hypercalcemia (Serum calcium >1 mg/dL (>0.25 mmol/L) higher than upper limit of normal or >11 mg/dL (>2.75 mmol/L))

o Renal insufficiency (Creatinine clearance<40 mL per min or serum creatinine >2 mg/dL (177 μmol/L))

o Anemia (Hemoglobin >2 g/dL (20 g/L) below lower limit of normal

o Bone lesions (≥1 osteolytic lesion on skeletal x-ray

• C2. ≥1 of the following biomarkers of malignancy: *

o Clonal bone marrow plasma cells ≥60%

o Involved:uninvolved sFLC ratio ≥100

o >1 focal lesion on MRI

---

Result

Diagnostic result Negative. Not positive for multiple myeloma by IMWG criteria

Diagnostic result Positive for multiple myeloma by IMWG criteria

Details:

Reset

* Required

For Multiple Myeloma Diagnostic Criteria assessment necessary to provide selection of the…

Read More

Revised Multiple Myeloma International Staging System (R-ISS) Online Calculator

Revised Multiple Myeloma International Staging System (R-ISS) – prognostication tool for myeloma patients based on…

Read More

Multiple Myeloma International Staging System (ISS) Online Calculator

Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely…

Read More